Vitamin D gets marketed for almost everything, which makes it hard to tell where the evidence is genuinely strong versus where it's a halo effect from bone-health research being stretched to cover mood and brain claims. The cognition and depression trial data is actually fairly specific about who benefits — and it's not "everyone." The short version: the effect exists, it's real, and it's concentrated almost entirely in people who start out low. Below is what the actual trials say, including a large negative result that's easy to miss if you only read the headlines.
Part of why the confusion persists is that the observational data looks much stronger than the interventional data. Low blood levels of vitamin D correlate with worse cognitive test scores and higher rates of depression across dozens of population studies — but correlation studies can't rule out reverse causation (people who are depressed or cognitively impaired tend to spend less time outdoors and generate less vitamin D from sunlight to begin with) or confounding by frailty, chronic illness, and age. Randomized trials, where researchers actually assign vitamin D or placebo and measure what happens, are the only way to separate "low vitamin D is a marker of poor health" from "low vitamin D causes poor brain outcomes." That's the evidence this article focuses on.
The cognition data: real, but concentrated in deficiency
A 2023 meta-analysis in Neuropsychology Review pooled randomized controlled trials of vitamin D supplementation and cognitive outcomes in older adults, and reported a small positive effect on global cognition across the whole pooled sample — substantially larger when the analysis was restricted to participants who were vitamin D deficient at baseline, and larger again among the higher-quality studies that specifically set out to correct a deficiency.1 The authors' own recommendation was that supplementation protocols should target and correct deficiency specifically, rather than assuming a blanket cognitive benefit for everyone.
We are deliberately not printing the effect sizes we quoted here previously. We could not re-access that paper to re-verify them during this review, and an unverified decimal is worse than no decimal — particularly for a "small" effect, where the difference between one figure and another changes whether it means anything at all. Treat the shape of this finding as well supported and the magnitude as something to read in the paper rather than take from us. If you want a number you can act on, it isn't an effect size: it's your own 25-hydroxyvitamin D result, which is why the blood tests worth asking for is the more useful companion piece to this one.
The mood and depression data: dose-dependent, and concentrated in people with symptoms
A 2025 dose-response meta-analysis pooled 31 RCTs (24,189 participants) on vitamin D3 and depressive symptoms.2 Each additional 1,000 IU/day was associated with a small reduction in depressive symptoms — SMD −0.32 (95% CI, −0.43 to −0.22), rated moderate certainty. The effect was considerably stronger in people who already had depression: SMD −0.57 (95% CI, −0.69 to −0.44) across 15 trials.
Three things in that same analysis deserve more attention than the headline. First, the much-quoted peak at 8,000 IU/day came out at SMD −2.04 with a 95% confidence interval of −3.77 to −0.31 — an interval that wide, from few data points, is a signal that the estimate is unstable, not that the effect is enormous. Treat it as a curiosity rather than a dosing recommendation. Second, the benefit shrank steadily with trial length: SMD −0.45 at eight weeks or less, −0.47 between 8 and 24 weeks, weaker beyond 24 weeks, and 0.14 — essentially nothing, pointing the wrong way — in trials running longer than 52 weeks. A treatment that only looks good in short trials is a pattern worth being suspicious of, and it sits awkwardly beside the idea of taking vitamin D indefinitely for mood. Third, vitamin D3 had no significant effect on anxiety symptoms, and the authors called for further high-quality trials before anything conclusive is said about it.
None of this means vitamin D is an antidepressant in any clinical sense — the reviewers framed it as an effect on symptom scores, not a treatment claim, and we're not making one either. For context on how that compares with interventions that do have robust depression evidence, see what the exercise trials actually show and what the omega-3 research actually shows, null results included in both.
What happens when the trial population isn't deficient? The VITAL-DEP result
The best test of that line is a study designed to answer exactly this question. VITAL-DEP, an ancillary depression-prevention study nested inside the large VITAL trial, randomized 18,353 U.S. adults (mostly in their late 60s and generally not vitamin D deficient at enrollment) to either 2,000 IU/day of vitamin D3 or placebo, and followed them for a median of 5.3 years.3 Published in JAMA in 2020, it found no significant difference between the vitamin D and placebo groups in the risk of developing depression, in recurrence of depressive symptoms, or in mood-score changes over time. This is one of the largest, longest-running vitamin D RCTs ever conducted for a mood-related endpoint, and it came back flatly negative — in a population that, by design, wasn't depleted to begin with.
That result isn't a contradiction of the meta-analyses above; it's the other half of the same pattern. The positive effects in the cognition and depression literature cluster almost entirely around people who are deficient or already symptomatic. VITAL-DEP enrolled generally healthy, generally replete older adults, and got a null result — which is exactly what you'd predict if the underlying mechanism is "correcting a deficiency helps," rather than "more vitamin D improves brain function regardless of where you started."
VITAL-DEP also matters because of its size and design, not just its result. Ancillary studies riding on a larger parent trial (the main VITAL trial was primarily designed to look at cardiovascular disease and cancer outcomes) can sometimes be underpowered for their secondary question, but 18,353 participants followed for over five years is a genuinely large sample for a mood endpoint, and a pre-registered, placebo-controlled design like this carries far more weight than any observational cohort. When a trial this size, this long, and this well-controlled comes back negative, that's a real finding, not an absence of evidence.
| Trial / analysis | Population | Result |
|---|---|---|
| Neuropsychology Review meta-analysis, deficient subgroup | Baseline vitamin D deficient | Substantially larger benefit on global cognition than in the full sample (exact effect size not reproduced here — see note above) |
| Neuropsychology Review meta-analysis, full sample | Mixed deficiency status | Small positive effect on global cognition |
| Psychological Medicine dose-response meta-analysis | People with existing depression (15 of 31 trials) | SMD −0.57 (95% CI −0.69 to −0.44); −0.32 per 1,000 IU/day overall; no effect on anxiety; negligible beyond 52 weeks |
| VITAL-DEP (JAMA, 2020) | Generally not deficient, not depressed | No significant effect on depression risk or mood |
The honest takeaway
All three bodies of evidence tell a consistent story: vitamin D's cognitive and mood benefits are real but conditional on actually being deficient or symptomatic to begin with — this isn't a supplement with a flat, universal brain-boosting effect for people who are already replete. That's a meaningfully more specific claim than the general marketing around it, and it's also why testing your levels before assuming you need a high dose is more useful here than for most supplements. It's also why the seasonal version of this question is worth separating from the supplement version: what shorter days actually do to mood and why sleep gets harder in winter both involve light exposure and body-clock timing that a capsule does not address. And if the worry underneath this is memory rather than mood, what's normal ageing and what needs an assessment is the better starting point, with the modifiable risk factors that actually carry population-level weight in the 45% dementia figure. If your levels are already adequate, the trial evidence doesn't support expecting a cognitive or mood lift from adding more.
Where this leaves the range
We don't currently sell a standalone vitamin D product, and our D3+K2 formulation has been discontinued from the Proco range. While it was part of the range, it existed for a related reason: D3 raises the body's ability to absorb calcium from the gut, and K2 helps direct that calcium toward bone rather than soft tissue — it was a bone- and cardiovascular-support pairing, not a cognition or mood product, and Proco wasn't making that claim for it. The two nutrients were paired because raising D3 without adequate K2 status is the more commonly discussed combination in the calcium-metabolism literature, not because K2 added anything to the brain evidence above — worth being clear about that distinction rather than letting the pairing imply a benefit it didn't have data for.
The evidence for correcting an actual vitamin D deficiency is solid across both bone and brain outcomes; what the cognition and mood trials tell you is to get your levels tested rather than assume a high dose will do more for your brain once you're already in range. A basic 25-hydroxyvitamin D blood test is inexpensive and widely available, and it's a more useful first step than picking a dose off a label — the trial evidence above simply doesn't support "more is better" once you're not deficient.
This article is for informational purposes only and has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. Speak with a healthcare provider before starting any new supplement, especially if you take medication or have an existing health condition.
References
- Effects of Vitamin D Supplementation on Cognitive Outcomes: A Systematic Review and Meta-Analysis. Neuropsychology Review, 2023. link.springer.com
- The effect of vitamin D supplementation on depression: a systematic review and dose-response meta-analysis of randomized controlled trials. Psychological Medicine, 2025. cambridge.org
- Okereke OI, et al. Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial (VITAL-DEP). JAMA, 2020;324(5):471-480. pubmed.ncbi.nlm.nih.gov
The same "benefit concentrated in deficiency, null in everyone else" pattern shows up for another heavily marketed nutrient, and we've traced it in B12 and brain fog. If you're taking vitamin D for mood and feel better despite already being replete, the placebo effect is a serious candidate rather than a slight.
Want to know if we add a dedicated Vitamin D product to the range? Join the list — no spam, just the range and the evidence behind it.